论文部分内容阅读
目的观察中药清肝解毒散结汤配合介入治疗原发性肝癌的远期疗效。方法将110例原发性肝癌住院患者随机分为治疗组(60例)与对照组(50例)。两组均采用Seldinger’s技术行肝动脉栓塞化疗,治疗组同时加用中药清肝解毒散结汤治疗。观察两组的远期生存率及生存质量。结果治疗后0·5年、1年、2年、3年生存率治疗组分别为88·33%、78·33%、51·67%、31·67%;对照组分别为84·00%、68·00%、30·00%、16·00%,2、3年生存率治疗组优于对照组(P<0·05),卡氏评分及体重变化方面来评价患者生存质量,两组比较差异均有显著意义(P<0·05)。结论中药清肝解毒散结汤配合介入治疗原发性肝癌,可以提高远期生存率和患者生存质量。
Objective To observe the long-term effect of Qinggan Jiedu Sanjie decoction combined with interventional treatment of primary liver cancer. Methods 110 patients with primary liver cancer were randomly divided into treatment group (60 cases) and control group (50 cases). Seldinger’s technique was used in both groups for hepatic arterial chemoembolization. The treatment group was additionally treated with traditional Chinese medicine Qinggan Jiedu Sanjie Decoction. The long-term survival and quality of life of the two groups were observed. Results The survival rates of 0.5, 1, 2 and 3 years after treatment were 88.33%, 78.33%, 51.67% and 31.67% in the treatment group and 84.00% in the control group respectively , 68.00%, 30.00%, 16.00%, 2 and 3-year survival rate in the treatment group were better than those in the control group (P <0 · 05), Karnofsky score and body weight changes, The differences between the two groups were significant (P <0.05). Conclusion Chinese medicine Qinggan Jiedu Sanjie Decoction combined with interventional treatment of primary liver cancer can improve the long-term survival rate and quality of life of patients.